Comparative Pharmacology
Head-to-head clinical analysis: ANTABUSE versus CAMPRAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTABUSE versus CAMPRAL.
ANTABUSE vs CAMPRAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversibly inhibits aldehyde dehydrogenase (ALDH), causing accumulation of acetaldehyde after alcohol ingestion, leading to aversive reaction.
Acamprosate (calcium acetylhomotaurinate) is thought to stabilize the chemical balance in the brain that is altered by alcohol dependence. Its exact mechanism is unknown, but it is believed to restore the balance of inhibitory (GABA) and excitatory (glutamate) neurotransmission, reducing the physiological symptoms of alcohol withdrawal and craving.
250 mg orally once daily, initiated after 12 hours of no alcohol intake; maintenance dose may be reduced to 125 mg daily based on tolerance.
666 mg (three 333 mg tablets) orally three times daily.
None Documented
None Documented
10.8 ± 3.5 hours (range 6-16 hours) for disulfiram; metabolites (e.g., 2-mercapto-2-methyl-4-butyl-γ-thiobutyrolactone) have prolonged half-lives up to 120-200 hours, contributing to sustained sensitivity to ethanol.
Terminal elimination half-life is 20-30 hours (mean 23 hours), supporting twice-daily dosing; steady-state achieved after 5-7 days
Primarily renal: 80-90% as metabolites (mainly diethyldithiocarbamate and its glucuronide, plus sulfate esters) within 24 hours; <20% fecal (unabsorbed disulfiram and biliary metabolites).
Renal: approximately 90% as unchanged drug; biliary/fecal: minimal (<10%)
Category C
Category C
Alcohol Deterrent
Alcohol Deterrent